Not even 5% [Fujifilm]
Not even surprisingGvHD: That's big costs in 2025.Partnership or CR in 2025.
Agree there is a funding gap that will need to be bridged by the end of the year.
Priorities have changed.Ross used to bang on about GVHD being the first to commercialize for Cynata. I wonder what KK would answer today. DFU by the looks?
I don't think the race to commercialisation has changed - GvHD is closer than DFU to commercial approval, IMO. But DFU
may be closer to revenue from a partnership. I can't imagine Cynata will get a worthwhile deal for GvHD in the US/EU/Aus while the Phase 2 trial is underway. They may get something for Japan, given the route to commercialisation is quicker over there. Something similar to what Dimerix received for their treatment of FSGS:
https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02900980-4O5EH6MV3TGF5CD1CKQCI53TUJ/pdf?access_token=0007KtdhO7FAFGby3MkBVHuTeaXD
But given we've seen nothing thus far, I'm not expecting anything until the results are out.
DFU, on the other hand, has only recently generated clinical data and this will take time to filter out to the right companies to get the right kind of partnership, if an appropriate deal is forthcoming. I'm sure they could get
a deal, it just might not be the
right deal (i.e. maybe the upfront payment or future royalties would be too low, given it is only P1 data).
Still talking up a deal that didn't happen in 2019 and now not mentioning who made the deal.Yeah. Is it better than nothing?
I mean, I don't blame them for trying to sell the value of the company now compared to 2019. It at least gets people pulling up some presentations from that era to see what changed between then and now.
(20min delay)